Dr Helfrid Hochegger is working to understand a new drug target in cancer cells that could be used together with palbociclib to treat triple negative breast cancer. This could provide a new treatment that could help more people with triple negative breast cancer survive.

Dr Rachael Natrajan is working to understand the role of a protein called SF3B1 in oestrogen receptor positive (ER+) breast cancer. She wants to find better ways to treat people whose breast cancer has changes to this protein.

Professor Janet Brown wants to determine if combining an immunotherapy drug avelumab with another drug, radium-233, could make the treatment more effective. She hopes this combination will improve the immune response to secondary breast cancer in the bone and at other sites in the body.

Drugs that help the immune system to detect and destroy cancer cells show promise as a treatment for triple negative breast cancer. Dr Anne Armstrong will be running a trial to see whether giving aspirin alongside one of these drugs makes the treatment more effective at controlling tumours.

Dr Rebecca Beeken wants to see if a diet programme that has been beneficial in other diseases could also benefit overweight women with breast cancer.

It’s thought that turning on the androgen receptor in some oestrogen receptor positive (ER+) breast cancers could help stop tumour growth. Dr Violeta Serra is investigating this theory further and is testing whether the androgen receptor could be a new treatment target.